Nuevas herramientas para la revisión de la medicación: PRM en pacientes en tratamiento con inhibidores de la bomba de protones / New tools for medication review: DRP in patients treatment with proton pump inhibitors

Objetivo Analizar mediante el programa de revisión de la medicación, Revisem®, la prevalencia de problemas relacionados con la medicación (PRM) en pacientes de la provincia de Valencia que estaban en tratamiento activo con inhibidores de la bomba de protones (IBP) en 2022. Diseño Estudio observacional descriptivo y retrospectivo. Material y métodos Se analizó el historial farmacoterapéutico (HFT) de 295 pacientes siguiendo los criterios propuestos por la Pharmaceutical Care Network Europe, utilizando la plataforma digital Revisem® del Muy Ilustre Colegio Oficial de Farmacéuticos de Valencia (MICOF). Resultados La edad media de los pacientes fue 81,8 ± 11,1 años y 66,4% fueron mujeres. Se detectó al menos un PRM en 97,3% de los pacientes. De los PRM analizados, 46,9% fueron interacciones, de las cuales 29,7% implicaban un IBP, siendo el omeprazol el de mayor frecuencia. Los PRM con IBP se relacionan de forma significativa con determinadas condiciones del paciente y grupos farmacológicos, como son el sexo femenino, la edad superior a 54 años y la polifarmacia. Conclusiones La plataforma digital Revisem®, permite la detección de una alta prevalencia de PRM a nivel provincial. La aplicación de nuevas herramientas tecnológicas para detectar la prevalencia de PRM es fundamental para optimizar los tratamientos de los pacientes. (AU)

Objective To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022. Design Descriptive and retrospective observational study. Material and methods The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF). Results The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy. Conclusions The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments. (AU)

[New tools for medication review: DRP in patients treatment with proton pump inhibitors]. / Nuevas herramientas para la revisión de la medicación: PRM en pacientes en tratamiento con inhibidores de la bomba de protones.

OBJECTIVE: To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022. DESIGN: Descriptive and retrospective observational study. MATERIAL AND METHODS: The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF). RESULTS: The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy. CONCLUSIONS: The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.

V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori / V Spanish Consensus Conference on Helicobacter pylori infection treatment

La infección por Helicobacter pylori es muy frecuente entre la población española y representa la causa fundamental de gastritis crónica, úlcera péptica y cáncer gástrico. Previamente se han llevado a cabo cuatro reuniones de Consenso sobre el manejo de la infección por H. pylori en España, la última de ellas en 2016. Los cambios en los esquemas de tratamiento y la creciente evidencia disponible al respecto han justificado la organización de esta V Conferencia Española de Consenso en mayo de 2021, centrada en el tratamiento de esta infección. Participaron 14 expertos sobre el tema, que realizaron una búsqueda sistemática de la evidencia científica y elaboraron una serie de recomendaciones que fueron sometidas a un proceso de interacción de votaciones anónimas seriadas mediante metodología Delphi. Para clasificar la evidencia científica y la fuerza de las recomendaciones, se utilizó el sistema GRADE. Este consenso establece, como punto de partida, un aumento de la exigencia en la eficacia de los tratamientos recomendados, que deben alcanzar, o preferiblemente superar, el 90% de curación al ser administrados empíricamente. De este modo, tanto en primera como en segunda línea se recomiendan tratamientos cuádruples con o sin bismuto, generalmente prescritos durante 14 días. Como tratamiento de primera línea se recomienda una pauta cuádruple concomitante sin bismuto (inhibidor de la bomba de protones, claritromicina, amoxicilina y metronidazol) o una combinación cuádruple con bismuto (inhibidor de la bomba de protones, bismuto, tetraciclina y metronidazol). En el presente consenso se revisan también con detalle otras alternativas de tratamiento de rescate.(AU)

Helicobacter pylori infection is very common in the Spanish population and represents the main cause of chronic gastritis, peptic ulcer, and gastric cancer. The last iteration of Spanish consensus guidelines on H. pylori infection was conducted in 2016. Recent changes in therapeutic schemes along with increasing supporting evidence were key for developing the V Spanish Consensus Conference (May 2021). Fourteen experts performed a systematic review of the scientific evidence and developed a series of recommendations that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. An eradication therapy, when prescribed empirically, is considered acceptable when it reliably achieves, or preferably surpass, 90% cure rates. Currently, only quadruple therapies (with or without bismuth) and generally lasting 14 days, accomplish this goal in first- and second-line therapies. A non-bismuth quadruple concomitant regimen (proton pump inhibitor, clarithromycin, amoxicillin, and metronidazole) or a quadruple bismuth-based combination (proton pump inhibitor, bismuth, tetracycline, and metronidazole), are recommended as first-line regimens. Rescue therapies after eradication failure and management of H. pylori infection in peptic ulcer disease were also reviewed.(AU)

V Spanish Consensus Conference on Helicobacter pylori infection treatment. / V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori.

Helicobacter pylori infection is very common in the Spanish population and represents the main cause of chronic gastritis, peptic ulcer, and gastric cancer. The last iteration of Spanish consensus guidelines on H. pylori infection was conducted in 2016. Recent changes in therapeutic schemes along with increasing supporting evidence were key for developing the V Spanish Consensus Conference (May 2021). Fourteen experts performed a systematic review of the scientific evidence and developed a series of recommendations that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. An eradication therapy, when prescribed empirically, is considered acceptable when it reliably achieves, or preferably surpass, 90% cure rates. Currently, only quadruple therapies (with or without bismuth) and generally lasting 14 days, accomplish this goal in first- and second-line therapies. A non-bismuth quadruple concomitant regimen (proton pump inhibitor, clarithromycin, amoxicillin, and metronidazole) or a quadruple bismuth-based combination (proton pump inhibitor, bismuth, tetracycline, and metronidazole), are recommended as first-line regimens. Rescue therapies after eradication failure and management of H. pylori infection in peptic ulcer disease were also reviewed.

Actualización en la interpretación de la medición del pH e impedanciometría / Updated interpretation of Impedance-pH monitoring

Resumen La enfermedad por reflujo gastroesofágico (ERGE) se define como el tránsito anormal del contenido gástrico hacia el esófago, que se da por una alteración de la barrera antirreflujo, causando síntomas o complicaciones. Para su correcto diagnóstico y abordaje terapéutico, se requiere de la integración de hallazgos clínicos, endoscópicos y monitorización del pH esofágico en 24 horas con o sin impedanciometría, la cual debe ser realizada con especificaciones técnicas, y su interpretación debe basarse en la mejor evidencia clínica disponible, con el objetivo de tener diagnósticos precisos que permitan tomar las mejores decisiones con los pacientes. Recientemente, en el Consenso de Lyon se han incorporado nuevas directrices para el diagnóstico de ERGE por monitorización de pH esofágico, las cuales se revisan en este artículo.

Abstract Gastroesophageal reflux disease (GERD) is defined as the abnormal transit of gastric contents into the esophagus. It is caused by an alteration of the anti-reflux barrier, causing multiple symptoms or complications. In order to achieve accurate diagnosis and proper therapeutic approach, integration of clinical findings, endoscopic findings and 24-hour esophageal pH monitoring, with or without impedancometry, is required. These tests must be performed following technical specifications and their interpretation must be based on the best clinical evidence available to obtain accurate diagnoses that allow making the best decisions to the benefit of patients. Recently, the Lyon Consensus incorporated new guidelines for the diagnosis of GERD by esophageal pH monitoring, which are reviewed in this paper.

Factors related to gastric neuroendocrine tumors. / Factores relacionados a tumores neuroendocrinos gástricos.

INTRODUCTION AND AIMS: An association between long-term use of proton pump inhibitors and the development of gastric neuroendocrine tumors has been reported, but it is still a subject of debate. The aims of the present study were to determine the presence of this association in a Mexican population and to identify the risk factors for developing gastric neuroendocrine tumors. MATERIALS AND METHODS: A case-control study was conducted, in which the cases were patients with a histopathologic diagnosis of gastric neuroendocrine tumor and the controls were patients evaluated through upper endoscopy. The controls were paired by age, sex, and endoscopic examination indication. Proton pump inhibitor use was considered prolonged when consumption was longer than 5 years. RESULTS: Thirty-three patients with gastric neuroendocrine tumor and 66 controls were included in the study. Eighteen (54.5%) patients in the case group were women, as were 39 (59%) of the patients in the control group. The median age of the patients in the case group was 55 years (minimum-maximum range: 24-82) and it was 54 years (minimum-maximum range:18-85) in the control group. A greater number of patients in the gastric neuroendocrine tumor group presented with gastric atrophy (p<0.0001) and autoimmune atrophic gastritis (p=0.0002), compared with the control group. No association between gastric neuroendocrine tumor and prolonged proton pump inhibitor use, sex, smoking, gastroesophageal reflux disease, Helicobacter pylori infection, diabetes mellitus, or autoimmune diseases was found in the univariate analysis. CONCLUSIONS: The results of our study showed no association between proton pump inhibitor use for more than 5 years and the development of gastric neuroendocrine tumor. The presence of gastric atrophy and autoimmune atrophic gastritis was associated with gastric neuroendocrine tumor development.

IV Spanish Consensus Conference on Helicobacter pylori infection treatment. / IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori.

Helicobacter pylori approximately infect 50% of Spanish population and causes chronic gastritis, peptic ulcer and gastric cancer. Until now, three consensus meetings on H.pylori infection had been performed in Spain (the last in 2012). The changes in the treatment schemes, and the increasing available evidence, have justified organizing the IVSpanish Consensus Conference (March 2016), focused on the treatment of this infection. Nineteen experts participated, who performed a systematic review of the scientific evidence and developed a series of recommendation that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. As starting point, this consensus increased the minimum acceptable efficacy of recommended treatments that should reach, or preferably surpass, the 90% cure rate when prescribed empirically. Therefore, only quadruple therapies (with or without bismuth), and generally lasting 14 days, are recommended both for first and second line treatments. Non-bismuth quadruple concomitant regimen, including a proton pump inhibitor, clarithromycin, amoxicillin and metronidazole, is recommended as first line. In the present consensus, other first line alternatives and rescue treatments are also reviewed and recommended.

Are the clinical guideline recommendations on gastroprotection being followed? A review in patients taking nonsteroidal anti-inflammatory drugs. / ¿Qué tanto se siguen las recomendaciones de las guías clínicas sobre gastroprotección? Una revisión en enfermos que consumen antiinflamatorios no esteroideos.

INTRODUCTION AND AIMS: The chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) can cause complications in the gastrointestinal tract. The use of proton pump inhibitors (PPIs) is recommended in high-risk patients to prevent them. OBJECTIVE: The aim of this article was to evaluate the gastroprotection measures taken in persons with chronic NSAID use. MATERIALS AND METHODS: A descriptive cross-sectional study was conducted. The clinical records were reviewed of patients seen as outpatients at the Rheumatology Department over a 4-month period, choosing those with chronic NSAID use, and intentionally looking for gastroprotection measures according to the recommendations published by the American College of Gastroenterology. RESULTS: A total of 417 patients (347 women; mean age: 48.12±14.2 years) were included. The most frequent diagnosis was rheumatoid arthritis (65%). Nine patients (2.1%) had a history of peptic ulcer, 48 (11.5%) patients were 65 years of age or older, 26 (6.2%) patients took NSAIDs and aspirin, and 130 (31.2%) took NSAIDs with steroids. Tests for Helicobacter pylori infection were done in just 53 cases, and there were positive results in only 9 (16%). Some risk for gastrointestinal toxicity was established in 211 cases and only 65 (30.8%) received gastroprotection. In contrast, 31 (15%) patients received gastroprotection when there was no indication for it. CONCLUSION: Prophylaxis with PPIs in chronic NSAID users was inadequately employed. It was not prescribed in the majority of patients (69.2%) and it was used with no justification in others (15%).

Pruebas diagnósticas en la enfermedad por reflujo gastroesofágico / Diagnostic tests in gastroesophageal reflux disease

En la actualidad la enfermedad por reflujo gastro esofágico (ERGE) no es una enfermedad simple y se tiene que considerar como una enfermedad heterogénea y multi-sintomática por lo que no hay una prueba estándar de oro. La decisión de que prueba utilizar, cuando utilizarla y cuál será su ganancia en el diagnóstico depende de varios factores. Para la evaluación estructural, la videoendoscopia se considera la prueba ideal ya que permite establecer la ausencia o presencia de erosiones y de complicaciones como el esófago de Barrett. La determinación del pH esofágico con impedanciometría es útil para establecer las características del contenido esofágico intraluminal (ácido, no ácido, mixto) y su asociación con los síntomas. Ante la presencia de síntomas como dolor torácico no cardíaco y disfagia, la manometría esofágica de alta resolución es la prueba más útil para evaluar la presencia de trastornos motores esofágicos. No obstante de que estas pruebas diagnósticas son útiles, su disponibilidad puede ser limitada, por lo que pruebas sencillas, como la utilización de cuestionario de síntomas o de prueba terapéutica con inhibidores de la bomba de protones se consideran como las pruebas iniciales ante la sospecha de ERGE.

Currently gastro esophageal reflux disease (GERD) is not a simple disease and must be considered as a heterogeneous and multi - symptomatic disease, so that there is no a gold standard test. The decision of which test to use, when to use it and what their diagnosis gain depends on several factors. For the structural assessment of esophagus, video endoscopy is considered as an ideal test because it allows the absence or presence of erosions and complications such as Barrett 's esophagus. Determination of esophageal pH impedance testing is useful in establishing the characteristics of intraluminal esophageal contents (acid, non-acid , mixed) and its association with symptoms. In the presence of symptoms such as non-cardiac chest pain and dysphagia, esophageal high resolution manometry is the most useful test to assess the presence of esophageal motor disorders. Notwithstanding that these diagnostic tests are useful, their availability may be limited, so simple tests, such as using symptom questionnaire or inhibitor therapeutic trial of proton pump are considered as initial tests for suspected GERD.

[Update on non-variceal gastrointestinal bleeding]. / Actualización en hemorragia gastrointestinal de origen no varicoso.

This article summarizes the main studies in the field of non-variceal gastrointestinal bleeding reported in the last American Congress of Gastroenterology (Digestive Disease Week) in 2013. Some of these studies have provided new knowledge and expertise in areas of uncertainty. In this context and among other findings, it has been reported that the administration of a proton pump inhibitor (PPI) prior to endoscopy or the early performance of endoscopy-within 6 hours of admission in patients with upper gastrointestinal bleeding (UGIB) (or colonoscopy within 24 hours in patients with lower gastrointestinal bleeding)-does not improve the prognosis of the event. It has also been reported that oral administration of a PPI after endoscopic hemostasis may produce a similar outcome to that of intravenously administered PPI in patients with upper gastrointestinal bleeding (UGIB). In the field of endoscopic therapy, the use of radiofrequency ablation for antral vascular ectasia is of interest. Regarding UGIB and nonsteroidal antiinflammatory drugs (NSAIDs), new data confirm the risk of cardiovascular events by stopping treatment with acetylsalicylic acid (ASA) after an episode of UGIB, the increased risk of UGIB when associating gastrotoxic drugs, and the need to identify both the gastrointestinal and cardiovascular risks of each NSAID and coxib when prescribing these agents. Finally, there is evidence that both environmental and genetic factors are involved in individual susceptibility to gastrointestinal bleeding.

Caracterización de pacientes con sangramiento digestivo alto / Characterization of patients presenting with high digestive bleeding

INTRODUCCIÓN. El sangramiento digestivo alto continúa siendo un problema de salud, y junto al abdomen agudo, las heridas y los traumatismos es prácticamente la razón de ser de una guardia de cirugía. MÉTODOS. Se realizó un estudio observacional, descriptivo y de corte transversal, cuyo universo estuvo constituido por todos los pacientes con este diagnóstico ingresados en el Hospital Docente Clinicoquirúrgico Joaquín Albarrán, entre enero del 2006 y diciembre del 2007 (2 años). RESULTADOS. Las edades más frecuentes estuvieron entre los 70 y 79 años, y fue más frecuente el sexo masculino y el antecedente de enfermedad cardiovascular. La melena fue la principal manifestación clínica. La endoscopia solo se realizó en el 25,16 por ciento de los casos, y en ella se observó principalmente duodenitis y gastritis. Como medidas terapéuticas más comunes se practicaron la hidratación y el uso sondas de Levine. Solo el 20,48 por ciento de los pacientes recibieron tratamiento contra Helicobacter pylori. La estadía hospitalaria promedio fue de 6 días o más. CONCLUSIONES. Las medidas generales de apoyo hemodinámico y la estrecha vigilancia de los pacientes pueden lograr salvaguardar sus vidas aunque no se disponga de un diagnóstico certero. La infección por Helicobacter pylori y su asociación a lesiones erosivas o ulcerosas de la mucosa gastroduodenal no ha sido totalmente asimilada en el pensamiento médico de los cirujanos. La función de la cirugía es cada vez menor en la terapéutica del sangramiento digestivo alto, a pesar de ser uno de los pilares fundamentales para enfrentarlo(AU)

INTRODUCTION. High digestive bleeding remains as health problem and together with acute abdomen, wounds and traumatisms is practically the main responsibility of a surgery rounds. METHODS. A cross-sectional, descriptive and observational study was conducted in a sample including all patients with this diagnosis admitted in Joaquín Albarrán Clinical Surgical Teaching Hospital between January, 2006 and December, 2007 (two years). RESULTS. The more frequent ages were between the patients aged 70 and 79 and also in male sex and the background was the cardiovascular disease. Melena was the leading clinical manifestation. Endoscopy was only performed in the 25,16 percent of cases noting mainly the presence of duodenitis and gastritis. Among the commonest therapeutical measures were hydration and the use of Levine's stents. Only the 20,48 percent of patients was treated against Helicobacter pylori. Average hospital stay was of 6 days or more. CONCLUSIONS. The application of general measures of hemodynamic support and a close surveillance of patients may to achieve safeguard their lives although there was not an accurate diagnosis. Helicobacter pylori and its association with erosive or ulcerous lesions of gastroduodenal mucosa haven't been assimilated in the physician's mind. The surgery role is decreasing in the high digestive bleeding therapy in spite of to be one the fundamental pillars for its confrontation(AU)

Caracterización de pacientes con sangramiento digestivo alto / Characterization of patients presenting with high digestive bleeding

El sangramiento digestivo alto continúa siendo un problema de salud, y junto al abdomen agudo, las heridas y los traumatismos es prácticamente la razón de ser de una guardia de cirugía. Se realizó un estudio observacional, descriptivo y de corte transversal, cuyo universo estuvo constituido por todos los pacientes con este diagnóstico ingresados en el Hospital Docente Clinicoquirúrgico Joaquín Albarrán, entre enero del 2006 y diciembre del 2007 (2 años). Las edades más frecuentes estuvieron entre los 70 y 79 años, y fue más frecuente el sexo masculino y el antecedente de enfermedad cardiovascular. La melena fue la principal manifestación clínica. La endoscopia solo se realizó en el 25,16 por ciento de los casos, y en ella se observó principalmente duodenitis y gastritis. Como medidas terapéuticas más comunes se practicaron la hidratación y el uso sondas de Levine. Solo el 20,48 por ciento de los pacientes recibieron tratamiento contra Helicobacter pylori. La estadía hospitalaria promedio fue de 6 días o más. Las medidas generales de apoyo hemodinámico y la estrecha vigilancia de los pacientes pueden lograr salvaguardar sus vidas aunque no se disponga de un diagnóstico certero. La infección por Helicobacter pylori y su asociación a lesiones erosivas o ulcerosas de la mucosa gastroduodenal no ha sido totalmente asimilada en el pensamiento médico de los cirujanos. La función de la cirugía es cada vez menor en la terapéutica del sangramiento digestivo alto, a pesar de ser uno de los pilares fundamentales para enfrentarlo(AU)

High digestive bleeding remains as health problem and together with acute abdomen, wounds and traumatisms is practically the main responsibility of a surgery rounds. METHODS. A cross-sectional, descriptive and observational study was conducted in a sample including all patients with this diagnosis admitted in "Joaquín Albarrán" Clinical Surgical Teaching Hospital between January, 2006 and December, 2007 (two years).The more frequent ages were between the patients aged 70 and 79 and also in male sex and the background was the cardiovascular disease. Melena was the leading clinical manifestation. Endoscopy was only performed in the 25,16 percent of cases noting mainly the presence of duodenitis and gastritis. Among the commonest therapeutical measures were hydration and the use of Levine's stents. Only the 20,48 percent of patients was treated against Helicobacter pylori. Average hospital stay was of 6 days or more. . The application of general measures of hemodynamic support and a close surveillance of patients may to achieve safeguard their lives although there was not an accurate diagnosis. Helicobacter pylori and its association with erosive or ulcerous lesions of gastroduodenal mucosa haven't been assimilated in the physician's mind. The surgery role is decreasing in the high digestive bleeding therapy in spite of to be one the fundamental pillars for its confrontation(AU)